Persistent hypercoagulable state in COVID-19: A case series of COVID-19 associated pulmonary embolism

4Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Coronavirus disease 2019 (COVID-19) has swept through the world with millions of cases and hundreds of thousands of deaths. COVID-19-associated coagulopathy has been recognized as the major cause of morbidity and mortality. To the best of our knowledge, a majority of the cases of coagulopathy have been reported in patients with moderate-to-severe COVID-19 and limited to observations during the recovery/postcytokine storm state. Herein, we report a case series of two patients with COVID-19 who developed pulmonary embolism in the late phase of the disease. This raised the hypothesis that the risk of hypercoagulability in patients with COVID-19 can persist until the recovery phase, which would warrant a follow-up with D-dimer and fibrinogen trending, as well as postdischarge thromboprophylaxis for at least 2 weeks during the recovery phase.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chan, K., Lim, S., Shaaban, H., Guron, G., & Slim, J. (2021). Persistent hypercoagulable state in COVID-19: A case series of COVID-19 associated pulmonary embolism. Journal of Global Infectious Diseases, 13(1), 38–41. https://doi.org/10.4103/jgid.jgid_180_20

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

67%

Lecturer / Post doc 4

19%

Professor / Associate Prof. 2

10%

Researcher 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

65%

Nursing and Health Professions 5

22%

Pharmacology, Toxicology and Pharmaceut... 2

9%

Neuroscience 1

4%

Save time finding and organizing research with Mendeley

Sign up for free